- Home
- FLYE vs AYTU Comparison
FLYE vs AYTU Comparison
Compare FLYE & AYTU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | FLYE | AYTU |
|---|---|---|
| Founded | 2018 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Aerospace | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.5M | 20.5M |
| IPO Year | 2024 | N/A |
Fundamental Metrics
Financial Performance| Metric | FLYE | AYTU |
|---|---|---|
| Price | $7.04 | $2.30 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $9.33 |
| AVG Volume (30 Days) | ★ 1.1M | 51.0K |
| Earning Date | 11-19-2025 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | $22,881,935.00 | ★ $63,696,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $47.30 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $3.83 | $0.95 |
| 52 Week High | $166.00 | $2.82 |
Technical Indicators
Market Signals| Indicator | FLYE | AYTU |
|---|---|---|
| Relative Strength Index (RSI) | 51.78 | 60.88 |
| Support Level | $6.55 | $2.05 |
| Resistance Level | $8.26 | $2.39 |
| Average True Range (ATR) | 2.48 | 0.10 |
| MACD | -0.23 | 0.03 |
| Stochastic Oscillator | 17.86 | 78.57 |
Price Performance
Historical ComparisonAbout FLYE Fly-E Group Inc. Common Stock
Fly-E Group Inc is an electric vehicle company that is principally engaged in designing, installing and selling smart electric motorcycles, electric bikes, electric scooters and related accessories under the brand Fly E-Bike. It also provides connectivity solutions and value-added services to their customers.
About AYTU Aytu BioPharma Inc.
Aytu BioPharma Inc is a specialty pharmaceutical company with a commercial portfolio of prescription therapeutics and consumer health products. The company's primary prescription products treat attention deficit hyperactivity disorder and other common pediatric conditions. It is building a complementary therapeutic development pipeline, including a prospective treatment (AR101/enzastaurin) for vascular Ehlers-Danlos Syndrome, a rare genetic disease resulting in high morbidity and a significantly shortened lifespan. The company operates one business segment consisting of various prescription pharmaceutical products sold through third parties.